Francis Medical Expands Vanquish System Use to Arizona for Prostate Cancer Ablation
Event summary
- Francis Medical completed its first commercial Vanquish® procedures in Arizona for prostate tissue ablation on March 5, 2026.
- The procedures were performed by Dr. Rahul Mehan at Verve Surgery Center in Mesa, Arizona.
- Vanquish received FDA 510(k) clearance in November 2025 and showed 91% elimination of targeted prostate cancer in VAPOR 2 study at 6 months.
- The system demonstrated low rates of urinary incontinence and erectile dysfunction, with high patient satisfaction at 12 months (93%).
The big picture
Francis Medical's expansion into Arizona marks a critical step in its controlled U.S. launch strategy for the Vanquish System. The transition from clinical trials to real-world urological practice underscores the company's operational rigor and the potential for minimally invasive alternatives in prostate cancer treatment. The system's positive patient-reported outcomes and low adverse event rates position it as a competitive option in a market dominated by treatments with significant side effects.
What we're watching
- Regulatory Expansion
- Whether Francis Medical can secure pre-market approval (PMA) for expanded indications based on longer-term VAPOR 2 outcomes.
- Market Adoption
- The pace at which the Vanquish System gains traction in commercial urological practice beyond clinical trials.
- Competitive Positioning
- How Vanquish's ability to ablate lesions in all prostate locations will differentiate it from existing ablation technologies.
Related topics